Probiotic Supplementation in Morbid Obese Patients Undergoing One Anastomosis Gastric Bypass-Mini Gastric Bypass (OAGB-MGB) Surgery: a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.

BACKGROUND: Bariatric surgery is known as one of the most effective treatments for sustainable weight loss; however, it may be associated with some complications. This study was designed to examine the effects of probiotic supplementation on some morbidities related to this surgery. METHODS: This was a placebo-controlled, double-blind, randomized clinical trial on morbid obese patients referred for One Anastomosis Gastric Bypass- Mini Gastric Bypass (OAGB-MGB) surgery to a tertiary referral center. Patients were assigned to receive a probiotic supplement (Familact®) or placebo from 4 weeks prior to surgery to 12 weeks after surgery. Anthropometric, biochemical, and inflammatory indices were evaluated at the beginning and the end of the study. RESULTS: At the end of study, significant improvements in some serum inflammatory markers, vitamin D status, and anthropometric measurements were observed (p < 0.05), which were significantly more in probiotic group rather than placebo group (p < 0.05). Moreover, significant improvements in glycemic indices and lipid profile were observed in both groups; however, these changes were not significantly different between the groups. There was no significant difference in serum levels of vitamin B12, folate, and homocysteine between groups at week 16 of the study. DISCUSSION: Our results indicate that probiotic supplementation promotes inflammatory markers, body weight loss, and status of vitamin D in patients undergoing OAGB-MGB bypass. Whether these findings will sustain in longer treatment duration remained to be elucidated in future studies. TRIAL REGISTRATION: This study has been registered at Clinicaltrial.gov with registration number NCT02708589.

Comparative effects of granulocyte-colony stimulating factor and colistin-alone or in combination on burn wound healing in Acinetobacter baumannii infected mice.

BACKGROUND AND OBJECTIVES: Burn wounds are one of the most important health problems all over the world because infection after burn can delay wound healing. Treating burn wounds with granulocyte-colony stimulating factor (G-CSF) is known to improve healing of injured tissue. In addition, colistin is prescribed as an effective treatment. The aim of this study was to evaluate the effect of G-CSF and colistin alone or in combination with G-CSF on wound healing of Acinetobacter baumannii (A. baumannii) infected burns. MATERIALS AND METHODS: This study was performed between January 2016 and April 2018. Burn wounds were experimentally induced in 36 mice. The wounds were inoculated with A. baumannii. In a 7-day period, burn wounds in each group were daily treated with subcutaneous injections (0.1 ml) of saline, G-CSF, colistin, and G-CSF plus colistin. After killing the animals, the size of the wound, number of leukocytes in the skin and microbial growth were evaluated. A value of p ≤ 0.05 was considered statistically significant. RESULTS: Wound healing in the G-CSF plus colistin group was significantly higher than the control group and the G-CSF group (P = 0.023 and P = 0.033, respectively). In G-CSF+colistin group, the number of leukocytes was higher than the control group considerably (P = 0.007). On the 7th day of treatment, number of positive bacterial cultures in the colistin and the G-CSF plus colistin groups was lower than other groups with a significant difference. CONCLUSION: Concurrent consumption of G-CSF and antibiotics can control burn infection and enhance the immune system towards wound healing.